Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary “Real Life” Experience

References

• Myers K, Hannah P. Anatomy of veins and lymphatics. In: Myers K, Hannah P, editors. Manual of Venous and Lymphatic Diseases. London, UK: Taylor & Francis Ltd; 2018:13–38.
   Google Scholar
• Thatipelli MR, McBane RD, Hodge DO, et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8(2):200–205. doi:10.1016/j.cgh.2009.09.019
   PubMed Web of Science ®Google Scholar
• Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474–1480. doi:10.1001/jamainternmed.2015.3184
   PubMed Web of Science ®Google Scholar
• Ageno W, Squizzato A, Togna A, et al. Incidental diagnosis of a deep vein thrombosis in consecutive patients undergoing a computed tomography scan of the abdomen: a retrospective cohort study. J Thromb Haemost. 2012;10(1):158–160. doi:10.1111/j.1538-7836.2011.04565.x
   PubMed Web of Science ®Google Scholar
• Ageno W, Dentali F, Squizzato A. How I treat splanchnic vein thrombosis. Blood. 2014;124(25):3685–3691. doi:10.1182/blood-2014-07-551515
   PubMed Web of Science ®Google Scholar
• Valeriani E, Riva N, Di Nisio M, et al. Splanchnic vein thrombosis: current perspectives. Vasc Health Risk Manag. 2019;15:449–461. doi:10.2147/VHRM.S197732
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64(1):179–202. doi:10.1016/j.jhep.2015.07.040
   PubMed Web of Science ®Google Scholar
• De Franchis R, Faculty BV. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–752. doi:10.1016/j.jhep.2015.05.022
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–e496S.
   PubMed Web of Science ®Google Scholar
• DeLeve LD, Valla DC, Garcia-Tsao G, et al. Vascular disorders of the liver. Hepatology. 2009;49(5):1729–1764.
   PubMed Web of Science ®Google Scholar
• Basili S, Pastori D, Raparelli V, et al. Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. Therap Adv Gastroenterol. 2018;6(11):1–10.
   Google Scholar
• Flores B, Trivedi HD, Robson SC, et al. Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci. 2017;3(3). doi:10.15761/JTS.1000182.
   PubMedGoogle Scholar
• Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–694.
   PubMed Web of Science ®Google Scholar
• Senzolo M, Riva N, Dentali F, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol. 2018;9(8):176. doi:10.1038/s41424-018-0043-2
   PubMedGoogle Scholar
• Riva N, Ageno W. Approach to thrombosis at unusual sites: splanchnic and cerebral vein thrombosis. Vasc Med. 2017;22(6):529–540. doi:10.1177/1358863X17734057
   PubMed Web of Science ®Google Scholar
• Senzolo M, Riggio O, Primignani M. Vascular disorders of the liver: recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Dig Liver Dis. 2011;43(7):503–514. doi:10.1016/j.dld.2010.11.006
   PubMedGoogle Scholar
• Riva N, Ageno W, Poli D, et al. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. J Thromb Haemost. 2015;13(6):1019–1027. doi:10.1111/jth.12930
   PubMed Web of Science ®Google Scholar
• Riva N, Ageno W, Schulman S, et al. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematol. 2016;3(6):e267–e275. doi:10.1016/S2352-3026(16)30020-5
   PubMed Web of Science ®Google Scholar
• Tufano A, Ageno W, Di Micco P, et al. Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thromb Res. 2018;164:69–74. doi:10.1016/j.thromres.2018.02.143
   PubMed Web of Science ®Google Scholar
• Tripodi A, Primignani M, Chantarangkul V, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology. 2009;137(6):2105–2111. doi:10.1053/j.gastro.2009.08.045
   PubMed Web of Science ®Google Scholar
• Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010;116(6):878–885. doi:10.1182/blood-2010-02-261891
   PubMed Web of Science ®Google Scholar
• Werner KT, Sando S, Carey EJ, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013;58:1776–1780. doi:10.1007/s10620-012-2548-y
   PubMed Web of Science ®Google Scholar
• Nery F, Chevret S, Condat B, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015;61(2):660–667. doi:10.1002/hep.27546
   PubMed Web of Science ®Google Scholar
• Qi X, Guo X, Yoshida EM, et al. Transient portal vein thrombosis in liver cirrhosis. BMC Med. 2018;16(1):83. doi:10.1186/s12916-018-1069-8
   PubMedGoogle Scholar
• Luca A, Caruso S, Milazzo M, et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012;265(1):124–132. doi:10.1148/radiol.12112236
   PubMed Web of Science ®Google Scholar
• Turco L, Schepis F, Villa E. The role of anticoagulation in treating portal hypertension. Current Hepatol Rep. 2018;17:200–208.
   PubMedGoogle Scholar
• Le W, Guo X, Xu X, et al. Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: results of a meta analysis. Adv Ther. 2020;38(1):495–520.
   PubMed Web of Science ®Google Scholar
• Villa E, Cammà C, Marietta M, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253–1260.e4. doi:10.1053/j.gastro.2012.07.018
   PubMed Web of Science ®Google Scholar
• Xu S, Guo X, Xu X, et al. Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis. Eur J Gastroenterol Hepatol. 2021. doi:10.1097/MEG.0000000000002123
   Web of Science ®Google Scholar
• Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2019;113:86–91.
   PubMed Web of Science ®Google Scholar
• Nagaoki Y, Aikata H, Daijyo K, et al. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48(1):51–58. doi:10.1111/hepr.12895
   PubMed Web of Science ®Google Scholar
• Janczak DT, Mimier MK, McBane RD, et al. Rivaroxaban and apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc. 2018;93(1):40–47. doi:10.1016/j.mayocp.2017.10.007
   PubMed Web of Science ®Google Scholar
• Naymagon L, Tremblay D, Zubizarreta N, et al. The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv. 2020;4(4):655–666. doi:10.1182/bloodadvances.2019001310
   PubMed Web of Science ®Google Scholar
• Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Mascarenhas J, Schiano T. Safety, efficacy, and long-term outcomes of anticoagulation in cirrhotic portal vein thrombosis. Dig Dis Sci. 2020. doi:10.1007/s10620-020-06695-4
   PubMed Web of Science ®Google Scholar
• Intagliata NM, Henry ZH, Maitland H, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016;61:1721–1727. doi:10.1007/s10620-015-4012-2
   PubMed Web of Science ®Google Scholar
• Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2019;113:86–91.
   PubMed Web of Science ®Google Scholar